Adma Biologics reported $438.51M in Equity Capital and Reserves for its fiscal quarter ending in September of 2026.





Equity Capital And Reserves Change Date
Adma Biologics USD 438.51M 30.3M Sep/2026
Alnylam Pharmaceuticals USD 3.6B 2.25B Sep/2026
BioCryst Pharmaceuticals USD -397.38M 56.9M Sep/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Novavax USD -216.86M 26.15M Sep/2026
Omeros USD -228.68M 15.13M Jun/2025
Takeda JPY 7.42T 141.7B Sep/2026